Fulcrum Therapeutics/$FULC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Ticker
$FULC
Sector
Primary listing
Employees
45
Headquarters
Website
FULC Metrics
BasicAdvanced
$379M
-
-$1.18
2.38
-
Price and volume
Market cap
$379M
Beta
2.38
52-week high
$8.50
52-week low
$2.32
Average daily volume
476K
Financial strength
Current ratio
24.415
Quick ratio
23.978
Long term debt to equity
2.462
Total debt to equity
3.532
Profitability
EBITDA (TTM)
-81.275
Management effectiveness
Return on assets (TTM)
-19.76%
Return on equity (TTM)
-30.00%
Valuation
Price to book
1.77
Price to tangible book (TTM)
1.77
Price to free cash flow (TTM)
-6.674
Free cash flow yield (TTM)
-14.98%
Free cash flow per share (TTM)
-1.049
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
261.44%
3-year earnings per share growth (CAGR)
-23.39%
What the Analysts think about FULC
Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.
Bulls say / Bears say
The 12 mg cohort of the Phase 1b PIONEER trial produced strong, clinically meaningful outcomes, including an absolute mean increase of 8.6% in fetal hemoglobin, 67% pan-cellular F-cell induction, a mean rise of 0.9 g/dL in hemoglobin, promising trends toward reduced VOC, and no treatment-related serious adverse events over 12 weeks.
As of Q2 2025, Fulcrum had $214.1 million in cash, cash equivalents, and marketable securities, giving it funding runway into 2028 to support clinical programs and discovery research.
R&D expenses fell to $13.0 million and G&A expenses to $6.8 million in Q2 2025 due to workforce reductions and program discontinuations, boosting operational efficiency and prolonging the company's financial runway.
Pipeline risk is elevated because Fulcrum's main program depends on the forthcoming 20 mg cohort data from the Phase 1b PIONEER trial, which is due by year-end and represents a critical value inflection point.
Fulcrum posted a net loss of $17.3 million for Q2 2025, compared to net income of $55.4 million in Q2 2024, highlighting ongoing operating losses without product revenue.
Collaboration revenue dropped to zero in Q2 2025 from $80 million in the previous year, eliminating a significant non-dilutive funding source and increasing the need to tightly manage cash burn.
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
FULC Financial Performance
Revenues and expenses
FULC Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulcrum Therapeutics stock?
Fulcrum Therapeutics (FULC) has a market cap of $379M as of September 16, 2025.
What is the P/E ratio for Fulcrum Therapeutics stock?
The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of September 16, 2025.
Does Fulcrum Therapeutics stock pay dividends?
No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Fulcrum Therapeutics dividend payment date?
Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) has a beta rating of 2.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.